The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

被引：0
|
作者：
Yang Zhang
Yuanyuan Zeng
Ting Liu
Wenwen Du
Jianjie Zhu
Zeyi Liu
Jian-an Huang
机构：
[1] the First Affiliated Hospital of Soochow University,Department of Respiratory Medicine
[2] Suzhou Key Laboratory for Respiratory Diseases,undefined
[3] Institute of Respiratory Diseases,undefined
[4] Soochow University,undefined
来源：
Respiratory Research | / 20卷
关键词：
PD-L1; EGFR-TKI; Drug resistance; TGF-β/Smad signalling; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
    Fu, Yulong
    Zhang, Yang
    Lei, Zhe
    Liu, Ting
    Cai, Tingting
    Wang, Anqi
    Du, Wenwen
    Zeng, Yuanyuan
    Zhu, Jianjie
    Liu, Zeyi
    Huang, Jian-an
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [32] Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
    Matikas, Alexios
    Mistriotis, Dimitrios
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CLINICAL LUNG CANCER, 2015, 16 (04) : 252 - 261
  • [33] PD-L1 Expression in Uncommon EGFR-Mutant Non-Small Cell Lung Cancer and Its Response to Immunotherapy
    Chen, K.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S747 - S747
  • [34] Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis
    Chen, Zhaoxin
    Wei, Jia
    Ma, Xiaoting
    Yu, Jing
    JOURNAL OF CANCER, 2020, 11 (03): : 686 - 695
  • [35] The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
    Du, Wenwen
    Sun, Lin
    Liu, Ting
    Zhu, Jianjie
    Zeng, Yuanyuan
    Zhang, Yang
    Wang, Xueting
    Liu, Zeyi
    Huang, Jian-An
    ONCOLOGY REPORTS, 2020, 44 (01) : 185 - 195
  • [36] Rationale and value of consolidative cranial local therapy in EGFR-mutant non-small cell lung cancer patients with baseline brain metastasis treated with first-line EGFR-TKIs
    Zeng, Ya
    Su, Xi
    Zhao, Yang
    Zhou, Yue
    Guo, Tiantian
    Chu, Xiao
    Chu, Li
    Yang, Xi
    Ni, Jianjiao
    Zhu, Zhengfei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
    Liu, Li
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer
    Zhang, Tieqiong
    Zheng, Chunlei
    Hou, Kezuo
    Wang, Jinyao
    Zhang, Ye
    Fan, Yibo
    Zhao, Huan
    Qu, Xiujuan
    Liu, Yunpeng
    Kang, Jian
    Che, Xiaofang
    Hu, Xuejun
    CELL BIOLOGY INTERNATIONAL, 2019, 43 (02) : 98 - 107
  • [39] Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy
    Matsumoto, Yoshiya
    Koh, Yasuhiro
    IMMUNOTHERAPY, 2020, 12 (07) : 431 - 438
  • [40] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345